|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010802,
umls-concept:C0023472,
umls-concept:C0023473,
umls-concept:C0030705,
umls-concept:C0043227,
umls-concept:C0332293,
umls-concept:C0443252,
umls-concept:C0596545,
umls-concept:C0871261,
umls-concept:C0935989,
umls-concept:C1518904,
umls-concept:C1522577,
umls-concept:C1552913,
umls-concept:C1563350,
umls-concept:C1563351,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-2-2
|
|
pubmed:abstractText |
Imatinib mesylate is the first line treatment for chronic myeloid leukemia. The advent of imatinib increased survival significantly in patients in an advanced phase of the disease. However, few long-term data on the outcome of these patients based on large, prospective and controlled trials are available.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-10219069,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-10594858,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-11042556,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-11287973,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-11877262,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-11986204,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-11986206,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-12114417,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-14607749,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-1569449,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-15988530,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-16463391,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-16533723,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-16601247,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-17264298,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-18048643,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-18165644,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-18367490,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-19407320,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-2204061,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-2406902,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-3162181,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-4970948,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-831755,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-8558198,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-8616716,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19144656-9676840
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
pubmed-author:AlbertiDanieleD,
pubmed-author:AlimenaGiulianaG,
pubmed-author:BaccaraniMicheleM,
pubmed-author:BrecciaMassimoM,
pubmed-author:CastagnettiFaustoF,
pubmed-author:LevatoLucianoL,
pubmed-author:LiberatiAnna MariaAM,
pubmed-author:LuattiSimonaS,
pubmed-author:MartinelliGiovanniG,
pubmed-author:MartinoBrunoB,
pubmed-author:MeranteSerenaS,
pubmed-author:PalandriFrancescaF,
pubmed-author:PaneFabrizioF,
pubmed-author:Rege-CambrinGiovannaG,
pubmed-author:RostiGianantonioG,
pubmed-author:SaglioGiuseppeG,
pubmed-author:SpecchiaGiorginaG,
pubmed-author:StagnoFabioF,
pubmed-author:TestoniNicolettaN
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
205-12
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19144656-Adult,
pubmed-meshheading:19144656-Aged,
pubmed-meshheading:19144656-Aged, 80 and over,
pubmed-meshheading:19144656-Cytogenetic Analysis,
pubmed-meshheading:19144656-Female,
pubmed-meshheading:19144656-Follow-Up Studies,
pubmed-meshheading:19144656-Humans,
pubmed-meshheading:19144656-Leukemia, Myeloid, Accelerated Phase,
pubmed-meshheading:19144656-Male,
pubmed-meshheading:19144656-Middle Aged,
pubmed-meshheading:19144656-Piperazines,
pubmed-meshheading:19144656-Pyrimidines,
pubmed-meshheading:19144656-Survival Rate,
pubmed-meshheading:19144656-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.
|
|
pubmed:affiliation |
Department of Hematology/Oncology L. and A. Seràgnoli S.Orsola Malpighi Hospital, University of Bologna, Bologna, Italy.
|
